RCS - Polarean Imaging PLC - Xenon MRI to be featured at ATS 2024 conference

Polarean ImagingAnnouncement

08/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240508:nRSH5084Na&default-theme=true

RNS Number : 5084N  Polarean Imaging PLC  08 May 2024

Polarean Imaging plc

("Polarean" or the "Company")

 

Xenon MRI to be featured at upcoming ATS 2024 conference

Polarean selected as a featured company at Respiratory Innovation Summit

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in
advanced magnetic resonance imaging ("MRI") of lung function, has been
selected as one of the featured companies and a poster presenter at the
American Thoracic Society's ("ATS") 2024 Respiratory Innovation Summit
("RIS"). The summit is scheduled to take place from 17-18 May in San Diego,
CA, at the Manchester Grand Hyatt San Diego.

 

The Respiratory Innovation Summit, a premier event in the field of pulmonary
medicine, unites innovators, investors, clinicians, and advocacy groups. The
meeting historically attracts more than 275 global leaders representing all
facets of the respiratory industry, including start-ups, venture capital,
government, academia, and clinicians.

 

Following the Respiratory Innovation Summit, members of Polarean's executive
team, including Christopher von Jako, Ph.D., Chief Executive Officer; Alex
Dusek, Chief Commercial Officer; and Kiarash Emami, Ph.D., VP of Technology
& Applications management, will be in attendance the 2024 ATS
International Conference, held from 19-22 May, at booth #2813.

 

This year, the breadth of Xenon MRI research and the number of displays is set
to outpace all previous years, with 33 presentations from 10 different sites
and multiple categories, including asthma, bronchopulmonary dysplasia, COPD,
COVID-19, cystic fibrosis, hematopoietic stem cell transplant, lung cancer
resection, radiation-induced lung injury, pulmonary arterial hypertension, and
thoracic insufficiency syndrome.

 

Christopher von Jako, Ph.D., CEO of Polarean, said: "We are delighted to have
been selected as a featured company at The Respiratory Innovation Summit,
which is testament to the value of our XENOVIEW technology being recognised
across lung clinicians and pulmonary drug developers. The RIS and the ATS
annual conference serve as invaluable venues to spotlight our Xenon MRI
platform, especially to those enthusiastic about fostering collaborative
partnerships. These events provide an unparalleled opportunity to elevate
awareness of our technology among clinicians, regulators, investors, and
potential pharmaceutical industry partners.

 

"As we strive to advance our commercialization strategy, the increase in Xenon
MRI posters and presentations marks significant strides in amplifying
understanding and enthusiasm for Xenon MRI and the spectrum of therapeutic
disciplines that could benefit from our technology."

 

See the listing below for details on the presentation title, abstract number,
session time, and location.

 

Enquiries:

 

 Polarean Imaging plc                                        www.polarean.com / www.polarean-ir.com (http://www.polarean-ir.com)
 Christopher von Jako, Ph.D., Chief Executive Officer        Via Walbrook PR
 Charles Osborne, Chief Financial Officer
  Polarean Media Contact:                                     +1 (919) 206-7900

 Alexis Opp                                                  aopp@polarean.com (mailto:aopp@polarean.com)

 Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)                                  +44 (0)20 7710 7600
 Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment
 Banking)
 Nick Harland (Corporate Broking)

 Walbrook PR         Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
                     (mailto:polarean@walbrookpr.com)
 Anna Dunphy / Phillip Marriage          Mob: +44 (0)7876 741 001 / +44 (0)7867 984 082

About Polarean

Polarean is a revenue-generating medical imaging technology company
revolutionizing pulmonary medicine through direct visualisation of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimise lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW™, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform. For the latest news and information about Polarean,
please visit www.polarean.com (http://www.polarean.com/) .

XENOVIEW IMPORTANT SAFETY INFORMATION

 

Indication

XENOVIEW™, prepared from the Xenon Xe 129 Gas Blend, is a hyperpolarized
contrast agent indicated for use with magnetic resonance imaging (MRI) for
evaluation of lung ventilation in adults and pediatric patients aged 12 years
and older.

 

Limitations of Use

XENOVIEW has not been evaluated for use with lung perfusion imaging.

 

CONTRAINDICATIONS

None.

 

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen
administered simultaneously with XENOVIEW inhalation can cause degradation of
image quality. For patients on supplemental oxygen, withhold oxygen inhalation
for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.

 

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may
cause transient hypoxemia in susceptible patients. Monitor all patients for
oxygen desaturation and symptoms of hypoxemia and treat as clinically
indicated.

 

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient)
in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse
Reactions in Pediatric and Adolescent Patients: In published literature in
pediatric patients aged 6 to 18, transient adverse reactions were reported:
blood oxygen desaturation, heart rate elevation, numbness, tingling,
dizziness, and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient increase in
heart rate was reported following hyperpolarized xenon Xe 129 administration.
XENOVIEW is not approved for use in pediatric patients less than 12 years of
age.

 

Please see full prescribing information at www.XENOVIEW.net

 

About The American Thoracic Society (www.thoracic.org)

The American Thoracic Society (ATS) improves global health by advancing
research, patient care, and public health in pulmonary disease, critical
illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown
to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and
sleep apnea, among other diseases.

 

 ATS Abstract Title                                                               Presentation Date     Abstract Number  Session and Location
 Hyperpolarized 129Xe MRI: What Additional Information Does It Provide?           May 18, 2024                           Session PG16

San Diego Convention Center, Room 6D (UpperLevel)
                                                                                  3:10 PM - 3:50 PM
 Quantifying the Impact of Cannabis Smoking in Lungs of Young Adults Using CT     May 19, 2024          1014             Session A29
 and Xe MRI

                                                                                  9:15 AM - 11:15 AM                     San Diego Convention Center, Room 6E (UpperLevel)
 Six-month Longitudinal Changes in129-XE and HRCT Imaging Metrics Tend to         May 19, 2024          1017             Session A29
 Associate With On-study COPD Exacerbations

                                                                                  9:15 AM - 11:15 AM
San Diego Convention Center, Room 6E (UpperLevel)
 Advanced 4D Hyperpolarized Gas Imaging of Ventilation and Dissolved Gas          May 19, 2024          1016             Session A29
 Biomarkers in COPD

                                                                                  9:15 AM - 11:15 AM                     San Diego Convention Center, Room 6E (UpperLevel)
 3-month Change in Hyperpolarized Xe MRI Membrane Uptake Predicts 6-month         May 19, 2024          P862             Session A47
 Change in Lung Function in Patients With Idiopathic Pulmonary Fibrosis

                                                                                  11:30 AM - 1:15 PM                     San Diego Convention Center, Area H (Hall H,Ground Level)

 Using Xenon MRI to Evaluate the Trajectories of Idiopathic Pulmonary Fibrosis    May 19, 2024          914              Session A104

                                                                                   2:15 PM - 4:15 PM                     San Diego Convention Center, Room 33A-C(Upper Level)
 Combining Hyperpolarized Xe MR Imaging and Spectroscopy to Estimate Pulmonary    May 19, 2024                           Session A97
 Vascular Resistance

                                                                                  3:39 PM - 3:51 PM                      San Diego Convention Center, Room 6D (UpperLevel)
 Magnetic Resonance Imaging Ventilation Phenotypes of Severe Asthma               May 19, 2024                           Session A99

                                                                                  3:39 PM - 3:51 PM                      Marriott Marquis San Diego Marina, PacificBallroom 24-26 (Ground Floor, North
                                                                                                                         Tower)
 Success and Feasibility of Multiple Breath Washout: Prospective Multi-center     May 20, 2024          421              Session B25
 Results From the Transpire Study

                                                                                  9:15 AM - 11:15 AM                     San Diego Convention Center, Room 25A-C(Upper Level)
 Improved Quantification of Ventilation Heterogeneity in Hyperpolarized Xenon     May 20, 2024          P170             Session B80-1
 MRI Using Physics-rooted Bias-field Correction

                                                                                  11:30 AM - 1:15 PM                     San Diego Convention Center, Area B (Hall A-B2,Ground Level)
 Addressing Healthy Aging Variations in Ventilation From Childhood to Older Age   May 20, 2024          P171             Session B80-1
 Using Xenon MRI

                                                                                  11:30 AM - 1:15 PM                     San Diego Convention Center, Area B (Hall A-B2,Ground Level)
 Assessing Radiation-induced Lung Injury Using a Chemical Shift Imaging-based     May 20, 2024          P176             Session B80-1
 CSSR Technique

                                                                                  11:30 AM - 1:15 PM                     San Diego Convention Center, Area B (Hall A-B2,Ground Level)
 Sex and Age-dependence of Xe MRI Cardiopulmonary Oscillations in Healthy         May 20, 2024          P188             Session B80-1
 Volunteers

                                                                                  11:30 AM - 1:15 PM                     San Diego Convention Center, Area B (Hall A-B2,Ground Level)
 Estimating Physiological Values of Membrane and Red Blood Cell Conductance       May 20, 202           P187             Session B80-1
 Using Xe Gas Exchange MRI

                                                                                  11:30 AM - 1:15 PM                     San Diego Convention Center, Area B (Hall A-B2,Ground Level)
 Increased BMI Is Associated With Elevated Membrane Uptake on Xe Gas Exchange     May 20, 2024          P178             Session B80-1
 MRI in Healthy Subjects

                                                                                  11:30 AM - 1:15 PM                     San Diego Convention Center, Area B (Hall A-B2,Ground Level)
 Establishing a Standardized Healthy Reference Distribution for Multi-site Xe     May 20, 2024          P172             Session B80-1
 Gas Exchange MRI Across Major Scanner Platforms

                                                                                  11:30 AM - 1:15 PM                     San Diego Convention Center, Area B (Hall A-B2,Ground Level)
 Quantifying Spatial Distribution of Ventilation Defects in Lung Imaging With     May 20, 2024          P174             Session B80-1
 Hyperpolarized Xenon MRI

                                                                                  11:30 AM - 1:15 PM                     San Diego Convention Center, Area B (Hall A-B2,Ground Level)
 Assessment of Gas Exchange With Hyperpolarized Xe MR Imaging in Mild             May 20, 2024          P190             Session B80-1
 Asthmatics When Administered a Vasodilator

11:30 AM - 1:15 PM                    San Diego Convention Center, Area B (Hall A-B2,Ground Level)
 129Xe MRI With Optimized Bias Field Correction to Assess Ventilation Gradients   May 20, 2024          P701             Session B80-2
 in Individuals With Normal Lung Function

                                                                                  11:30 AM - 1:15 PM
 Research and Clinical Applications of Hyperpolarized 129Xe MRI                   May 20, 2024                           Session B91

                                                                                  3:00 PM - 3:15 PM                      San Diego Convention Center, Room 24A-C(Upper Level)
 Assessment of Obstructive and Restrictive Lung Disease Via MRI in                May 21, 2024          404              Session C29
 Bronchopulmonary Dysplasia Patients

                                                                                  9:15 AM - 11:15 AM                     San Diego Convention Center, Room 25A-C(Upper Level)
 Changes in Individual Ventilation Defects in Cystic Fibrosis After Initiation    May 21, 2024          405              Session C29
 of Modulator Therapy, in the Hypoint Trial

                                                                                  9:15 AM - 11:15 AM                     San Diego Convention Center, Room 25A-C(Upper Level)
 Xe MRI and Oscillometry Evidence ofImproved Small Airways Dysfunction After      May 21, 2024          407              Session C29
 6-weeks ICS/LABA/LAMA Therapy in Moderate Asthma

                                                                                  9:15 AM - 11:15 AM                     San Diego Convention Center, Room 25A-C(Upper Level)
 Comparison of CT-based Measurements of Ventilation and Perfusion to              May 21, 2024          410              Session C29
 Ventilation and Gas Exchange Measurements From Hyperpolarized Xe MRI

                                                                                  9:15 AM - 11:15 AM                     San Diego Convention Center, Room 25A-C(Upper Level)
 CT Mucus Score Predicts Response to 6-weeks ICS/LABA/LAMA in Moderate Asthma     May 21, 2024          413              Session C29

                                                                                  9:15 AM - 11:15 AM                     San Diego Convention Center, Room 25A-C(Upper Level)
 Xe MR Evidence of Abnormal Gas-exchange in Mild-moderate and Severe Asthma       May 21, 2024          418              Session C29

                                                                                  9:15 AM - 11:15 AM                     San Diego Convention Center, Room 25A-C(Upper Level)
 Ventilation Defect Burden Quantified by Technegas SPECT and Xe MRI Predicts      May 21, 2024          420              Session C29
 Lung Cancer Resection Outcomes

                                                                                  9:15 AM - 11:15 AM                     San Diego Convention Center, Room 25A-C(Upper Level)
 Rapid and Persistent 6-week Response to ICS/LABA/LAMA in Mild-moderate Asthma    May 21, 2024          P690             Session C71

                                                                                                                         San Diego Convention Center, Area F (Hall A-B2,Ground Level)

                                                                                  11:30 AM - 1:15 PM
 Evaluation of Xenon Gas Phase and Dissolved Phase Delays Using Dynamic           May 21, 2024          P156             Session C73
 129Xe-hyperpolarized MRI in Pre-clinical Thoracic Insufficiency Syndrome Model

                                                                                                                         San Diego Convention Center, Area F (Hall A-B2,Ground Level)

                                                                                  11:30 AM - 1:15 PM
 Xe MRI Reveals Regional Gas-exchange Abnormalities in Cystic Fibrosis Lung       May 21, 2024          P174             Session C74
 Disease

                                                                                                                         San Diego Convention Center, Area F (Hall A-B2,Ground Level)

                                                                                  11:30 AM - 1:15 PM
 Quantitative Characterization of Regional Ventilation and Perfusion in           May 21, 2024          P186             Session C75
 Patients With Persistent COVID-19 Symptoms Using Hyperpolarized Xe MRI and

 Dual Energy CT                                                                                                          San Diego Convention Center, Area F (Hall A-B2,Ground Level)

                                                                                  11:30 AM - 1:15 PM
 The EXPLAIN (Hyperpolarised Xenon Magnetic Resonance Pulmonary Imaging in        May 21, 2024          P195             Session C75
 Patients With Long-COVID) Study: The Primary Outcome

                                                                                                                         San Diego Convention Center, Area F (Hall A-B2,Ground Level)

                                                                                  11:30 AM - 1:15 PM
 Same-day and Six-week Repeatability of Hyperpolarized Xe MRI Measures in         May 22, 2024          306              Session D109
 Patients With Pulmonary Arterial Hypertension

11:00 AM - 1:00 PM                    San Diego Convention Center, Room 28C-E(Upper Level)

 

PLC-RNS-2332

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKZGGKLNDGDZM